U.S. markets close in 4 hours 25 minutes
  • S&P 500

    -17.62 (-0.46%)
  • Dow 30

    -275.35 (-0.89%)
  • Nasdaq

    -11.86 (-0.09%)
  • Russell 2000

    -17.32 (-0.80%)
  • Crude Oil

    -0.11 (-0.21%)
  • Gold

    -5.10 (-0.27%)
  • Silver

    -0.22 (-0.86%)

    -0.0038 (-0.32%)
  • 10-Yr Bond

    -0.0460 (-4.22%)

    -0.0027 (-0.20%)

    +0.0240 (+0.02%)

    +429.25 (+1.28%)
  • CMC Crypto 200

    +5.59 (+0.83%)
  • FTSE 100

    -57.42 (-0.86%)
  • Nikkei 225

    +190.84 (+0.67%)

Growth Investors: Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Simply Wall St
·3 min read

Celebrations may be in order for Bicycle Therapeutics plc (NASDAQ:BCYC) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have sharply increased their revenue numbers, with a view that Bicycle Therapeutics will make substantially more sales than they'd previously expected. The stock price has risen 7.7% to US$13.60 over the past week, suggesting investors are becoming more optimistic. Could this big upgrade push the stock even higher?

After this upgrade, Bicycle Therapeutics' five analysts are now forecasting revenues of US$25m in 2020. This would be a sizeable 194% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$20m in 2020. It looks like there's been a clear increase in optimism around Bicycle Therapeutics, given the considerable lift to revenue forecasts.

View our latest analysis for Bicycle Therapeutics

NasdaqGS:BCYC Past and Future Earnings May 8th 2020
NasdaqGS:BCYC Past and Future Earnings May 8th 2020

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. One thing stands out from these estimates, which is that Bicycle Therapeutics is forecast to grow faster in the future than it has in the past, with revenues expected to grow 194%. If achieved, this would be a much better result than the 20% annual decline over the past year. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 19% per year. Not only are Bicycle Therapeutics' revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. They're also forecasting more rapid revenue growth than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Bicycle Therapeutics.

Looking to learn more? At least one of Bicycle Therapeutics' five analysts has provided estimates out to 2024, which can be seen for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.